Acumen Pharma Commences Patient Dosing in ALTITUDE-AD Phase 2 Trial

Keenness Drugs, Inc., a clinical-stage biopharmaceutical organization fostering a novel therapeutic that objectives harmful solvent amyloid beta oligomers (AßOs) for the treatment of Alzheimer's disease (AD), declared that the main patient has been dosed with sabirnetug (ACU193) in the ALTITUDE-AD stage 2 clinical trial intended to assess the clinical viability and wellbeing of sabirnetug in patients with early AD.

“Today marks a significant milestone for Acumen and the Alzheimer’s community as we begin the Phase 2 trial of sabirnetug,” said Daniel O’Connell, chief executive officer of Acumen. “Sabirnetug is at the forefront of the next generation of Alzheimer's therapies, with encouraging phase 1 results supporting its novel mechanism of action and selectivity for toxic amyloid beta oligomers. These results have led to a high level of investigator and patient interest in sabirnetug’s therapeutic potential and a strong start to the trial.”

ALTITUDE-AD (NCT06335173) is a phase 2 multi-center, randomized, double-blind, placebo-controlled clinical trial that is now recruiting in the United States and Canada, with additional research sites planned for Europe and the United Kingdom. The trial will enroll about 540 persons with early Alzheimer's disease who will be randomly assigned to receive one of two dose levels of sabirnetug (35mg/kg or 50mg/kg once every four weeks) or a placebo. Dose levels were determined to approach maximal target engagement using modeling from the INTERCEPT-AD phase 1 research data.